cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • April 2017 •
  • 77 pages •
  • Report ID: 5001782
Immuno-Oncology Deal Trends, 2012–16

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups signed more than 300 immuno-oncology deals between 2012 and 2016, growing at a compound annual growth rate of 48%. Aggregate deal value over this period was $48bn. The majority of deals involved development of drugs for solid tumors, especially lung cancer and melanoma, and the target of choice was programmed death-ligand 1 (PD-L1). Bristol-Myers Squibb and Merck & Co led in transaction volume.

More than 50% of the immuno-oncology deals between 2012 and 2016 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

There was nearly an even split in terms of how combinations were structured, with just over half consisting of an anti-cancer immunotherapy target with a non-immunotherapy target, and the rest consisting of two anti-cancer immunotherapies. Among the immuno-oncology targets, PD-L1 was most often the backbone in the combination, and was paired up with vascular endothelial growth factor receptor or DNA synthesis or methylase inhibitors more often than with any other target.
Throughout this report, the information on deals and trial collaborations is derived from three main sources: Informa’s Medtrack, Strategic Transactions, and Trialtrove.